X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

Combination Drug Development and Five Year New Chemical Entity (NCE) Exclusivity

Yuvraj_pawp by Yuvraj_pawp
4th April 2015
in FDA Approvals, Research & Development

The US Food and Drug Administration (FDA) recently announced that fixed-combination drugs (FCD) comprised of at least one NCE will be eligible for five years of exclusivity. [1]

The FDA explained that it has revised its interpretation of the term ‘drug’ for the purpose of exclusivity eligibility from ‘drug product’ to ‘drug substance’.

Five-year NCE exclusivity determination will apply to each drug substance in the product, not the drug product as a whole. FDA’s previous interpretation of the terms meant that FCDs containing NCEs were only eligible for three years of exclusivity. [2]

The announcement came in the form of a newly finalized guidance entitled New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products. To view the guidance, click here.

While three-year exclusivity bars approvals of the same drug products until expiry, five-year exclusivity may bar 505(b)(2) and generally bars ANDA submissions until expiry.

The obvious de facto effect is that five years of NCE exclusivity may yield greater than five years of competition-free marketing.

According to regulations cited in the guidance “If a drug product that contains a new chemical entity was approved … in an application submitted under section 505(b) of the act, no person may submit a 505(b)(2) application or abbreviated new drug application under section 505(j) of the act for a drug product that contains the same active moiety as in the new chemical entity for a period of five years from the date of approval of the first approved new drug application”.[3]

However, the new guidance also includes a description of FDA’s ‘Umbrella Policy’ under which the FDA has allowed certain drug products subsequently developed that contain the same active moiety to share the balance of the original product’s five-year NCE exclusivity.[4]

The FDA noted in the new guidance that combination therapy is emerging as the standard of care in certain disease settings including cancer, cardiovascular disease, and infectious disease.

Furthermore, the FDA wishes to incentivize the development of certain fixed-combination products. [5] [6]

The key to success in combination drug development is the employment of strategic planning principles beginning at project conception. The engagement of a pharmaceutical consultant with experience in 505(b)(2) submissions should be addressed at the earliest stages of development.

Pharmaceutical Development Group (PDG) is a global pharmaceutical consultant with extensive experience in the strategic development of 505(b)(2) drug products.

From identification and choice of viable candidates through ensuring the existence of cost-effective commercialization strategies, PDG is unique in its ability to comprehensively integrate products, dosage forms, populations and FDA regulatory pathways.

Please feel free to contact us for more information.

About the author
Charles Jaap is vice-president of Operations and Business Development for PDG.

The opinions and statements in this press release are solely those of Charles Jaap and do not necessarily reflect the views of PDG.

Previous Post

RSSL Doubles QP Course Dates Following Increased Demand

Next Post

Biomedica Launches First CE Marked FGF23 ELISA Assay In Europe and Asia

Related Posts

Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows
Manufacturing

Commercial Success In New Biopharmaceutical Innovation Era

21st May 2022
Manufacturing

Proteros and AstraZeneca Boost Collaboration Agreement

18th May 2022
JSR Life Sciences Amsphere A3 Integrated into the Commercial Manufacturing of FDA-Approved Antibody Therapy
FDA Approvals

JSR Life Sciences Amsphere A3 Integrated into the Commercial Manufacturing of FDA-Approved Antibody Therapy

22nd March 2022
SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory
Middle East and South Asia

SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory

22nd March 2022
Lynparza From AZ As Breast Cancer Cure Gets FDA Approval
FDA Approvals

Lynparza From AZ As Breast Cancer Cure Gets FDA Approval

15th March 2022
New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System
FDA Approvals

New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

31st January 2022
Next Post

Biomedica Launches First CE Marked FGF23 ELISA Assay In Europe and Asia

Latest News

Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Manufacturing

Abbott India Affirms That The Medicines Are Not Their Own

5th July 2022
Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In